Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models

  title={Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models},
  author={Ayan Dey and T.M. Chozhavel Rajanathan and Harish Chandra and Hari P.R. Pericherla and Sanjeev Kumar and Huzaifa S. Choonia and Mayank Bajpai and Arun Kumar Singh and Anuradha Sinha and Gurwinder Saini and Parth S. Dalal and Sarosh Vandriwala and Mohammed A. Raheem and Rupesh D. Divate and Neelam L. Navlani and Vibhuti Sharma and Aashini Parikh and Siva Prasath and Sankar Rao and Kapil Maithal},
  pages={4108 - 4116}
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
In this review, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.
Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
The currently available vaccines against SARS-CoV-2 in development are summarized, with the focus on the concepts of mRNA vaccines, their antigen selection, delivery and optimization to increase the immunostimulatory capability of mRNA as well as its stability and translatability.
DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model
A novel DNA vaccine comprised of the SARS-CoV-2 spike protein fused with CD40 ligand (CD40L) serving as both a targeting ligand and molecular adjuvant was reported, which reduced weight loss and suppressed viral replication in the lungs and nasal turbinates of challenged animals and was shown to reduce lung pathology more effectively than the DNA vaccine devoid of CD40L.
Advances in COVID-19 mRNA vaccine development
This review summarizes current knowledge on the structural characteristics, antigen design strategies, delivery systems, industrialization potential, quality control, latest clinical trials and real-world data of COVID-19 mRNA vaccines as well as mRNA technology.
DNA vaccines for SARS-CoV-2: toward third-generation vaccination era
This vaccine platform has additional benefits compared to traditional vaccination strategies like strong cellular immune response, higher safety margin, a simple production process as per cGMP norms, lack of any infectious agent, and a robust platform for large-scale production.
Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
This article reviews the candidate targets, vaccine types, research and development status, progress of SARS-CoV-2 vaccines, and the effectiveness of neutralizing antibodies against Sars-Co V-2 mutants induced by these vaccines, to provide a reference for follow-up research and prevention.
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
The structural and replicatory features of SARS-CoV-2 are summarized, and focused on vaccine-mediated disease prevention strategies like vaccine antigen selection, vaccine research, and vaccine application are focused on.
Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2
The protective immunity induced in mice vaccinated with the pNS1/E/D2 candidate is evaluated and compared to the responses elicited by immunization with the former vaccines isolated or in combination.
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019


Immunogenicity of a DNA vaccine candidate for COVID-19
An optimized DNA vaccine candidate encoding the SARS-CoV-2 spike antigen is generated, demonstrating induction of specific T cells and neutralizing antibody responses in mice and guinea pigs, and these initial results support further development of this vaccine candidate.
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
These SARS-CoV vaccines all induced antibody and protection against infection with SARS -CoV, however, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARsCoV components was induced.
Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
The study demonstrated immunogenicity and protective efficacy of the vaccine candidate, ZyCoV-D in rhesus macaques.
Monoclonal Antibodies for Prevention and Treatment of COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic has created a worldwide crisis and inspired an urgent search for prevention and treatment of severe acute respiratory syndrome coronavirus 2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
Results indicate that these DNA vaccines are able to induce virus-specific memory B cells and long-lasting antibodies in swine, which were of higher levels than those obtained with a commercial formalin-inactivated JE vaccine.
Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts
These data build on the repeated-dose toxicology studies performed to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications.
A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody
Response in Rabbits and Nonhuman Primates
It is demonstrated, for the first time, that a spring-powered DSJI device is capable of effectively delivering a DNA vaccine to NHPs and whether this HPS DNA vaccine will elicit a strong immune response in humans, requires clinical trials.
Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
Inactivated Mers-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS- coV infection that is similar to that found with inactivated SARS-Cov vaccines from SARS -CoV infection.